Plexium harnesses a differentiated platform of proprietary technologies and approaches to establish a robust and diverse portfolio of monovalent targeted protein degrader therapeutics
Plexium is the premier, next-generation targeted protein degradation (TPD) company. We lead the way in the rational design and discovery of Monovalent Direct Degraders and Molecular Glues.
Through our comprehensive best-in-class TPD platform powered by a proprietary ultra-high throughput cell-based screening (uHTS) technology, we are pushing the boundaries of TPD — creating limitless possibilities.
At Plexium, we are bound by our shared commitment to delivering life-changing medicines to patients. Our world-class team is highly collaborative, integrated and rooted in an entrepreneurial spirit that fuels our innovation.
Executive Chairman, Plexium
Chief Executive Officer
Partner, TCG X
Partner, Lux Capital
Managing Partner, Pivotal Bioventure Partners
Managing Director at BVF Partners L.P.
Operating Partner, DCVC Bio
President and CEO of RAPT Therapeutics
We are currently partnering with AbbVie to discover new monovalent degraders for neurological conditions.
